Investors

cecava is a German biotech company with a clear mission: to revolutionize cancer treatment through individualized immunotherapies. At the heart of its innovations is a clinically tested, IP protected personalized peptide vaccine approach, which has already demonstrated significant survival benefits for patients. The company is led by an experienced senior management team and guided by a scientific advisory board of international neuro-oncology experts.

We are planning to start a phase 1 trial on GBM as soon as possible.

For early investors we have designed a very attractive convertible note equipped with a 2-year term, 8% interest and a 25% discount on the conversion event.

Download our investor handout or convertible note to learn more about investment opportunities with cecava.

Further information on live events and press releases can be found in our communications section.

We are happy to connect with anyone interested in our company and work. Simply fill out the form or send us an email: investors@cecava.com